BridgeBio Pharma Change in Assets/Liabilities 2018-2024 | BBIO
BridgeBio Pharma annual/quarterly change in assets/liabilities history and growth rate from 2018 to 2024. Change in assets/liabilities can be defined as represents any other changes in assets/liabilities
- BridgeBio Pharma change in assets/liabilities for the quarter ending December 31, 2024 was $0.001B, a 23% decline year-over-year.
- BridgeBio Pharma change in assets/liabilities for the twelve months ending December 31, 2024 was $-0.199B, a 2510.12% decline year-over-year.
- BridgeBio Pharma annual change in assets/liabilities for 2024 was $0.001B, a 23% decline from 2023.
- BridgeBio Pharma annual change in assets/liabilities for 2023 was $0.001B, a 98.1% decline from 2022.
- BridgeBio Pharma annual change in assets/liabilities for 2022 was $0.043B, a 207.21% decline from 2021.
BridgeBio Pharma Annual Change in Assets/Liabilities
(Millions of US $) |
| 2024 |
$1 |
| 2023 |
$1 |
| 2022 |
$43 |
| 2021 |
$-40 |
| 2020 |
$-10 |
| 2019 |
$-30 |
| 2018 |
$-7 |
| 2017 |
$-4 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$6.575B |
$0.222B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
